MYLIP抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela and Jurkat cell lysates, Primary antibody: P10447(MYLIP Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10447(MYLIP Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

MYLIP (Myosin Regulatory Light Chain Interacting Protein), also known as IDOL (Inducible Degrader of LDL Receptor), is an E3 ubiquitin ligase that plays a critical role in cholesterol homeostasis. It mediates the ubiquitination and subsequent degradation of the low-density lipoprotein receptor (LDLR), thereby regulating cellular cholesterol uptake. Discovered in 2009. MYLIP/IDOL is transcriptionally controlled by liver X receptors (LXRs), nuclear receptors that respond to excess cellular cholesterol. This regulatory pathway provides a complementary mechanism to sterol-regulatory element-binding proteins (SREBPs) in maintaining lipid balance.

Antibodies targeting MYLIP are essential tools for studying its expression, localization, and function in metabolic and neurodegenerative diseases. Research has linked MYLIP dysregulation to atherosclerosis, hypercholesterolemia, and Alzheimer’s disease, highlighting its therapeutic potential. MYLIP antibodies are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to investigate protein-protein interactions, particularly with LDLR and related trafficking proteins. Recent studies also explore MYLIP's role beyond cholesterol metabolism, including immune modulation and neuronal development. Commercial and custom antibodies are often validated for specificity across human, mouse, and rat models, supporting both basic research and drug discovery efforts targeting lipid-related disorders.